KILLINGWORTH — The Connecticut Affiliate of the Huntington’s Disease Society of America is holding their 10th annual Team Hope Walk at Chatfield Hollow State Park in Killingworth.
The Team Hope Walk program is HDSA’s largest grassroots event set for May 15, and will be held on over 100 cities across the country.
All proceeds support HDSA’s fight to improve the lives of people affected by HD and their families. We thank National sponsors Lundbeck and Teva Pharmaceuticals and local sponsors, Oak & Velvet, Backus Hospital, Suzio York-Hill, Tatas Family Restaurant, HDHat, The Mark, Devine Brothers, Kindred Healthcare at Laurel Lakes, The Lloyd Family and the Nixon Family. We also thank Kohl’s Cares Associates in Action for volunteering to help the day of the walk.
Registration will begin at 9 a.m. and the walk kicks off at 10 a.m.
The Connecticut Affiliate is asking for support of the community to become a sponsor, form a team, walk as an individual, donate products or volunteer to help with the event activities. This 1 1/2 mile scenic walk is a fun, family-friendly event that includes food, music, raffle/auction items and children’s activities, including face painting, balloon animals and magic. Dogs are welcome and children can ride their bikes. There is also trout fishing if you have your license.
The walk is handicap accessible. Sonar, the Hartford Wolfpack mascot will be there. You only need $25 sponsorship per person to participate.
Huntington’s disease (HD) is a devastating, hereditary, degenerative brain disorder that results in a loss of cognitive, behavioral and physical control, and for which, presently, there is no cure and only one FDA-approved treatment for one of the symptoms. HD slowly diminishes the affected individual’s ability to walk, think, talk and reason. Symptoms usually appear in an individual between 30 and 50 years of age and progress over a 10 to 25 year period. Cases of Juvenile HD have been diagnosed in children as young as two years of age. More than 30,000 people in the United States are currently diagnosed. Each of their siblings and children has a 50 percent risk of developing the disease, therefore 250,000 are at risk. There are thousands of people in CT affected by this fatal disease.
Although medications can relieve some symptoms in certain individuals, research has yet to find a means of conquering or even slowing the deadly progression. However, recent research has found a way to silence the defective gene. There is hope for the future but we need our support.